Dr Aparna Rao
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
37 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study
DOI: 10.1136/jitc-2025-0145642025
Journal article
Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases
DOI: 10.1007/s11060-025-05121-x2025
Journal article
1637P FDG PET/CT response as a predictive biomarker of long-term outcomes and patterns of recurrence to immune checkpoint inhibitor (ICI) therapy in unresectable cutaneous melanoma
DOI: 10.1016/j.annonc.2025.08.22652025
Conference Proceedings
1636P Gonadal toxicity in men receiving immune checkpoint inhibitors for melanoma
DOI: 10.1016/j.annonc.2025.08.22642025
Journal article
Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts
DOI: 10.1038/s42255-025-01338-22025
Research grants (ARC, NHMRC, MRFF)
Identifying Novel Metabolic Biomarkers and Therapeutic Targets in Patients With Melanoma
2014
Journal article
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
DOI: 10.1158/2159-8290.CD-13-0440
RECENT SCHOLARLY WORKS
2025
Journal article
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review.
DOI: 10.1200/jco.2025.43.16_suppl.95322025
Journal article
Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
DOI: 10.1200/jco.2025.43.16_suppl.e215682025
Conference Proceedings
Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies.
DOI: 10.1200/jco.2025.43.16_suppl.95772025
Journal article
Anxiety, depression, fear of cancer recurrence (FCR) and health-related quality of life (HRQL) in people with melanoma receiving adjuvant therapies.
DOI: 10.1200/jco.2025.43.16_suppl.95662025
Journal article
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
DOI: 10.1136/jitc-2025-011551